3,5-diiodoindole-2-carboxylic acid ethyl ester | 623918-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,5-diiodoindole-2-carboxylic acid ethyl ester
• 英文别名: ethyl 3,5-diiodo-1H-indole-2-carboxylate
• CAS: 623918-45-6
• 化学式: C₁₁H₉I₂NO₂
• 分子量: 441.007
• InChiKey: DHFLRHXTVGBDRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-diiodoindole-2-carboxylic acid ethyl ester 在 盐酸 、 锌 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以4.75 g的产率得到ethyl 5-iodo-1H-indole-2-carboxylate
  参考文献：
  名称：

  5-碘-1H-吲哚-2-羧酸乙酯的制备

  摘要：

  摘要 本文描述了一种简便的两步法，用于从可商购的 1H-吲哚-2-羧酸乙酯制备 5-碘-1H-吲哚-2-羧酸乙酯 (1)，采用区域选择性 C3，C5-二碘化，然后通过锌介导的 C3-脱卤反应。

  DOI：

  10.1081/scc-120021830
• 作为产物：
  描述：

  吲哚-2-羧酸乙酯 在 sodium periodate 、 硫酸 、 碘 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以100%的产率得到3,5-diiodoindole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  5-碘-1H-吲哚-2-羧酸乙酯的制备

  摘要：

  摘要 本文描述了一种简便的两步法，用于从可商购的 1H-吲哚-2-羧酸乙酯制备 5-碘-1H-吲哚-2-羧酸乙酯 (1)，采用区域选择性 C3，C5-二碘化，然后通过锌介导的 C3-脱卤反应。

  DOI：

  10.1081/scc-120021830
• 作为试剂：
  描述：

  ethyl 5-iodo-1H-indole-2-carboxylate 以 3,5-diiodoindole-2-carboxylic acid ethyl ester 为溶剂， 生成 ethyl 5-iodo-3-(chlorosulfonyl)-1-(phenylsulfonyl)-1H-indole-2-carboxylate
  参考文献：
  名称：

  Combination therapy

  摘要：

  本发明涉及使用至少两种Akt抑制剂的组合或一种同时是Akt抑制剂和蛋白激酶抑制剂的化合物来治疗癌症的方法，该方法包括向哺乳动物施用来自以下组合中选择的至少两种治疗剂的量，该组合包括Akt抑制剂和蛋白激酶抑制剂。该发明还涉及制备这种组合物的方法。

  公开号：

  US20040102360A1

文献信息

• [EN] NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2013010904A1

  公开（公告）日：2013-01-24

  The present invention is concerned with novel substituted indole derivatives of Formula (I) wherein R1, R2, R3, A1, A2, A3, Y and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及具有以下式（I）中R1、R2、R3、A1、A2、A3、Y和X所定义含义的新型取代吲哚衍生物。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新型化合物的方法，包含该化合物作为活性成分的药物组合物，以及将该化合物用作药物的用途。
• Tyrosine kinase inhibitors
  申请人：Dinsmore J. Christopher

  公开号：US20050261496A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及一种能够抑制、调节和/或调控受体型和非受体型酪氨酸激酶信号转导的化合物。本发明的化合物具有包含磺酰基吲哚基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• TYROSINE KINASE INHIBITORS
  申请人：Dinsmore Christopher J.

  公开号：US20100041652A1

  公开（公告）日：2010-02-18

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及一种能够抑制、调节和/或调控受体型和非受体型酪氨酸激酶信号转导的化合物。本发明的化合物具有包含吲哚-磺酰胺基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASES
  申请人：MERCK & CO INC

  公开号：WO2004014851A3

  公开（公告）日：2004-09-02
• <i>N</i>-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists
  作者：Amy Hauck Newman、Peter Grundt、George Cyriac、Jeffrey R. Deschamps、Michelle Taylor、Rakesh Kumar、David Ho、Robert R. Luedtke

  DOI：10.1021/jm900095y

  日期：2009.4.23

  In the present report, the D3 receptor pharmacophore is modified in the 2,3-diCl- and 2-OCH3-phenylpiperazine class of compounds with the goal to improve D3 receptor affinity and selectivity. This extension of structure-activity relationships (SAR) has resulted in the identification of the first enantioselective D3 antagonists (R- and S-22) to be reported, wherein enantioselectivity is more pronounced at D3 than at D2, and that a binding region on the second extracellular loop (E2) may play a role in both enantioselectivity and D3 receptor selectivity. Moreover, we have discovered some of the most D3-selective compounds reported to date that show high affinity (K-i = 1 nM) for D3 and similar to 400-fold selectivity over the D2 receptor subtype. Several of these analogues showed exquisite selectivity for D3 receptors over >60 other receptors, further underscoring their value as in vivo research tools. These lead compounds also have appropriate physical characteristics for in vivo exploration and therefore will be useful in determining how intrinsic activity at D3 receptors tested in vitro is related to behaviors in animal models of addiction and other neuropsychiatric disorders.